Fast Track Group FTRK 深 沪
已收盘 08-14 16:00:00 美东时间
0.286
-0.024
-7.74%
华盛通- 最 高0.3067
- 今 开0.3067
- 成交量 5.59万股
- 最 低 0.286
- 昨 收 0.31
- 总市值 6238.375
- 52周最高 1.04
- 市盈率 静 --
- 换手率 256.09%
- 52周最低 0.2664
- 委 比 98.68%
- 总股本 2.18万
- 历史最高 9.69
- 量 比 0.64
- 振 幅 6.68%
- 历史最低 0.2664
- 每 手 1
- 风险率 0.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434
Alterity Therapeutics has been granted a new U.S. patent for ATH434, extending its protection to at least 2045. This strengthens its intellectual property and long-term commercial potential, particularly as the company prepares for Phase 3 trials in Multiple System Atrophy (MSA). The patent covers a crystalline form of ATH434's mesylate salt and its use in treating neurological conditions, enhancing market protection and enabling future developme...
08-12 11:05
Jazz Pharmaceuticals to acquire Actio Biosciences for $1.32B
Jazz Pharmaceuticals (JAZZ) announced on Monday that it will acquire privately held Actio Biosciences for $820M upfront and up to $500M in potential milestones. The acquisition strengthens the company...
08-10 20:54
Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027
Greenwich LifeSciences, a biopharmaceutical company, has extended the lock-up period for its directors, officers, and pre-IPO investors until January 31, 2027. During this time, these individuals cannot sell their shares unless the Board of Directors modifies the agreement. The company also plans to implement a leak-out plan for restricted sales after the lock-up period. CEO Snehal Patel highlighted the company's participation in BIO and BIO-Euro...
08-10 10:00
Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress
Context Therapeutics Inc. reported its Q2 2026 financial results, with cash reserves of $43 million expected to fund operations into Q4 2027. The company prioritized its CTIM-76 and CT-202 clinical programs, with initial data expected in Q2 2027. CTIM-76 showed encouraging interim results in platinum-resistant ovarian cancer patients, while CT-202 is set to begin its first patient dosing in Q3 2026. CT-95 development was discontinued. R&D expense...
08-05 20:14
Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications
Rein Therapeutics announced the publication of clinical data on LTI-03 in Nature Communications, showing significant reductions in lung scarring and inflammation markers in IPF patients. The first-in-human study demonstrated that LTI-03 was well-tolerated and safe, with no systemic absorption. The data support the ongoing Phase 2 RENEW trial, which aims to evaluate LTI-03's efficacy in improving lung function. This marks a promising step in treat...
08-04 12:00
Zai Lab receives Orphan Drug status for ADC for neuroendocrine carcinomas
The US FDA has granted Orphan Drug status to Zai Lab's (LAB) antibody-drug conjugate zocilurtatug pelitecan for neuroendocrine carcinomas. The asset previously received Fast Track designation for othe...
08-03 21:28
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Candel Therapeutics granted stock options to three new employees, totaling 30,800 shares with an exercise price of $10.01 per share, under its 2025 Inducement Plan. The options vest 25% after one year and the remaining 75% in 36 monthly installments, contingent on continued employment. The company focuses on developing multimodal immunotherapies for cancer, with key products CAN-2409 and CAN-3110 in clinical trials, receiving FDA designations inc...
08-03 20:05
Radiopharm Theranostics Reports Business Update
Radiopharm Theranostics reported positive Phase 2b results for imaging agent RAD 101, with 93% of evaluable patients achieving the primary endpoint. The company plans to initiate a Phase 3 registrational trial for RAD 101 in Q4 2026. Additionally, the company raised approximately $12.5 million through an institutional offer and launched a $6 million Share Purchase Plan. RAD 204 showed promising early clinical signs in a Phase 1 trial, with the fi...
07-31 11:00
INmune Bio Receives R&D Rebates of Approximately $4.6 Million
INmune Bio Inc. received a $4.2 million R&D cash rebate from Australia and an additional $0.4 million from the UK, totaling $4.6 million. These rebates strengthen the company's financial position, extend its cash runway, and support the advancement of CORDStrom™ toward regulatory filings. CEO David Moss highlighted the significance of these non-dilutive funds in preserving momentum for near-term milestones. The rebates were generated through gove...
07-31 11:00
FAST TRACK GROUP's Fast Track Entertainment Subsidiary Collaborates To Establish Offline Regional Launchpad Initiative
FAST TRACK GROUP (NASDAQ:FTRK) ("Fast Track" or the "Company"), a leading entertainment-focused event management and celebrity agency company, announced that its subsidiary Fast Track Entertainment ("FTE"), alongside the regional division of one of the world’s largest major music label groups (the "...
07-27 20:33
